SRR8943022
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.590
- G2M_CHECKPOINT+0.420
- MYC_TARGETS_V2+0.340
- MYC_TARGETS_V1+0.320
- PANCREAS_BETA_CELLS+0.310
- FATTY_ACID_METABOLISM+0.300
- DNA_REPAIR+0.290
- SPERMATOGENESIS+0.250
- CHOLESTEROL_HOMEOSTASIS+0.240
- BILE_ACID_METABOLISM+0.200
Top 10 suppressed
- ANGIOGENESIS-0.480
- ALLOGRAFT_REJECTION-0.470
- TGF_BETA_SIGNALING-0.470
- IL6_JAK_STAT3_SIGNALING-0.460
- TNFA_SIGNALING_VIA_NFKB-0.440
- INFLAMMATORY_RESPONSE-0.410
- WNT_BETA_CATENIN_SIGNALING-0.400
- INTERFERON_GAMMA_RESPONSE-0.380
- NOTCH_SIGNALING-0.380
- KRAS_SIGNALING_UP-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR26320088 | — | — | 0.924 |
| 2 | SRR1516068 | — | — | 0.902 |
| 3 | R55 | — | — | 0.881 |
| 4 | TCGA-HD-A634-01A-11R-A28V-07 | — | — | 0.880 |
| 5 | SRR12202476 | — | — | 0.880 |
| 6 | SRR1516065 | — | — | 0.873 |
| 7 | SRR8518130 | — | E | 0.869 |
| 8 | TCGA-CN-A6V7-01A-12R-A34R-07 | — | — | 0.867 |
| 9 | TCGA-66-2754-01A-01R-0980-07 | — | cohortA3 | 0.865 |
| 10 | 96a00cc6-3880-4f03-a08d-73d284787971 | — | — | 0.865 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.590 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.420 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.340 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.320 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.240 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.140 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.090 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.090 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.050 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.030 | Idelalisib | — uncovered |